Cargando…

Pulmonary Vascular Platform Models the Effects of Flow and Pressure on Endothelial Dysfunction in BMPR2 Associated Pulmonary Arterial Hypertension

Endothelial dysfunction is a known consequence of bone morphogenetic protein type II receptor (BMPR2) mutations seen in pulmonary arterial hypertension (PAH). However, standard 2D cell culture models fail to mimic the mechanical environment seen in the pulmonary vasculature. Hydrogels have emerged a...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Amico, Reid W., Faley, Shannon, Shim, Ha-na, Prosser, Joanna R., Agrawal, Vineet, Bellan, Leon M., West, James D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164056/ https://www.ncbi.nlm.nih.gov/pubmed/30158434 http://dx.doi.org/10.3390/ijms19092561

Ejemplares similares

Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling
por: Pickworth, Josephine, et al.
Publicado: (2017)

Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension
por: Egnatchik, Robert A., et al.
Publicado: (2017)

Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension
por: Long, Lu, et al.
Publicado: (2015)

Functional Changes in Pulmonary Arterial Endothelial Cells Associated with BMPR2 Mutations
por: Wang, Hu, et al.
Publicado: (2014)

Copy-number variation in BMPR2 is not associated with the pathogenesis of pulmonary arterial hypertension
por: Johnson, Jennifer A, et al.
Publicado: (2009)

The genetics of pulmonary arterial hypertension in the post-BMPR2 era
por: Fessel, Joshua P., et al.
Publicado: (2011)

Adverse effects of BMPR2 suppression in macrophages in animal models of pulmonary hypertension
por: West, James, et al.
Publicado: (2020)

BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series)
por: Frump, Andrea, et al.
Publicado: (2018)

BMPR2 spruces up the endothelium in pulmonary hypertension
por: Xiong, Jianhua
Publicado: (2015)

A potential adverse role for leptin and cardiac leptin receptor in the right ventricle in pulmonary arterial hypertension: effect of metformin is BMPR2 mutation-specific
por: Talati, Megha, et al.
Publicado: (2023)

SCUBE1 Controls BMPR2-Relevant Pulmonary Endothelial Function: Implications for Diagnostic Marker Development in Pulmonary Arterial Hypertension
por: Sun, Wei, et al.
Publicado: (2020)

Chronic Allergic Inflammation Causes Vascular Remodeling and Pulmonary Hypertension in Bmpr2 Hypomorph and Wild-Type Mice
por: Mushaben, Elizabeth M., et al.
Publicado: (2012)

Physiologic and molecular consequences of endothelial Bmpr2 mutation
por: Majka, Susan, et al.
Publicado: (2011)

PTPN1 Deficiency Modulates BMPR2 Signaling and Induces Endothelial Dysfunction in Pulmonary Arterial Hypertension
por: Ali, Md Khadem, et al.
Publicado: (2023)

Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension
por: Andruska, Adam, et al.
Publicado: (2018)

Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2
por: Novoyatleva, Tatyana, et al.
Publicado: (2021)

Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension
por: Pousada, Guillermo, et al.
Publicado: (2017)

Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations
por: Pfarr, Nicole, et al.
Publicado: (2011)

Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells
por: Yang, Xudong, et al.
Publicado: (2011)

Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient
por: Raamsteeboers, Aniek J., et al.
Publicado: (2014)

Inflammation induces endothelial‐to‐mesenchymal transition and promotes vascular calcification through downregulation of BMPR2
por: Sánchez‐Duffhues, Gonzalo, et al.
Publicado: (2019)

A Novel BMPR2 Mutation Associated with Pulmonary Arterial Hypertension in an Octogenarian
por: Johri, Shilpa, et al.
Publicado: (2010)

Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension
por: Hara, Hironori, et al.
Publicado: (2017)

15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation
por: Ahn, Kyung Jin, et al.
Publicado: (2019)

Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation
por: Montani, David, et al.
Publicado: (2021)

Author Correction: Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2
por: Novoyatleva, Tatyana, et al.
Publicado: (2022)

Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension
por: Austin, Eric D, et al.
Publicado: (2009)

CircGSAP alleviates pulmonary microvascular endothelial cells dysfunction in pulmonary hypertension via regulating miR-27a-3p/BMPR2 axis
por: Sun, Yuanyuan, et al.
Publicado: (2022)

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis
por: Evans, Jonathan D W, et al.
Publicado: (2016)

Mutation in BMPR2 Promoter: A ‘Second Hit’ for Manifestation of Pulmonary Arterial Hypertension?
por: Viales, Rebecca Rodríguez, et al.
Publicado: (2015)

BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients
por: Song, Jie, et al.
Publicado: (2020)

Structural consequences of BMPR2 kinase domain mutations causing pulmonary arterial hypertension
por: Chaikuad, Apirat, et al.
Publicado: (2019)

Bmpr2 mutant mice are an inadequate model for studying iron deficiency in pulmonary hypertension
por: Zhang, Vida, et al.
Publicado: (2022)

Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy
por: Dai, Lingling, et al.
Publicado: (2022)

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?
por: Theobald, Vivienne, et al.
Publicado: (2023)

Modeling Neurovascular Disorders and Therapeutic Outcomes with Human-Induced Pluripotent Stem Cells
por: Bosworth, Allison M., et al.
Publicado: (2018)

The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension
por: Ormiston, Mark L., et al.
Publicado: (2015)

The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations
por: Dunmore, Benjamin J., et al.
Publicado: (2013)

CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension
por: Kabwe, Jane Chanda, et al.
Publicado: (2022)

Pulmonary arterial hypertension drugs can partially restore altered angiogenic capacities in bmpr2‐silenced human lung microvascular endothelial cells
por: Tielemans, Birger, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_npnlbhorrumkgmu2ime5mdft7i